Skip to main content
Top
Published in: International Urology and Nephrology 10/2014

01-10-2014 | Urology - Original Paper

The effect of pentoxifylline on penile cavernosal tissues in ischemic priapism-induced rat model

Authors: Fikret Erdemir, Fatih Firat, Fatma Markoc, Dogan Atilgan, Bekir Suha Parlaktas, Yunus Emre Kuyucu, Yusuf Gencten

Published in: International Urology and Nephrology | Issue 10/2014

Login to get access

Abstract

Introduction

Priapism is defined as persisting (>4 h), painful and abnormal tumescence that can occur without sexual stimulation. Three subtypes priapisms are seen—the non-ischemic priapism, intermittent and the ischemic priapism. In ischemic priapism, there is an abnormality in the veno-occlusive mechanism, resulting in venous stasis and accumulation of deoxygenated blood within the penile cavernosal tissue. Cavernosal tissue necrosis develops after extended period of ischemia and is eventually replaced by fibrotic tissue. It may results in erectile dysfunction if not treated promptly. Although, standard treatment of the ischemic priapism is penile aspiration and intracavernosal alpha-adrenergic agents, new oral agents have been investigated to reduce the cavernosal damage. In this study, the effect of different doses of pentoxifylline on cavernosal tissues was evaluated.

Materials and methods

Thirty-six male Wistar albino rats, age 5.5–6 months and weighing 250–300 g, were used in this study. The rats were randomly divided into five groups. In Group 1 (n = 7), the control group, only penectomy was performed. In Group 2 (n = 8), after 1 h of ischemic priapism, penectomy was performed. Group 3 (n = 7) received daily a 10 mg oral pentoxifylline for 4 weeks after 1 h of ischemic priapism, group 4 (n = 7) received a daily 30 mg oral pentoxifylline for 4 weeks after 1 h of ischemic priapism, and group 5 (n = 7) received a daily 100 mg oral pentoxifylline for 4 weeks after 1 h of ischemic priapism. At the completion of a 4-week period, penile tissues were obtained. Before penile tissues were obtained, intracavernosal pressures measured with electrical field stimulation and smooth muscle collagen ratio were evaluated pathologically.

Results

Electrical field stimulation-induced intracavernosal relaxation decreased in group 2 compared with group 1 (p < 0.05). Electrical field stimulation-induced relaxation enhanced in the group 3, 4 and 5 compared to group 2 (p < 0.05). In group 2, the collagen density was significantly higher than group 1. Administration of pentoxifylline reduced the collagen density caused by ischemic priapism in groups 3, 4 and 5 compared with group 2.

Conclusion

The results of the present study showed that ischemic priapism caused damage in the penile tissues of rats, and treatment with pentoxifylline reduced the harmful effects of ischemic priapism.
Literature
1.
go back to reference Papadopoulos I, Kelâmi A (1988) Priapus and priapism. From mythology to medicine. Urology 32:385–386PubMedCrossRef Papadopoulos I, Kelâmi A (1988) Priapus and priapism. From mythology to medicine. Urology 32:385–386PubMedCrossRef
2.
go back to reference Lue TF (1998) Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Walsh P, Retik AB, Vaughan ED, Wein AJ (eds) Campbell’s Urology, vol 3, 7th edn. Saunders Company, Philadelphia, pp 1157–1174 Lue TF (1998) Physiology of penile erection and pathophysiology of erectile dysfunction and priapism. In: Walsh P, Retik AB, Vaughan ED, Wein AJ (eds) Campbell’s Urology, vol 3, 7th edn. Saunders Company, Philadelphia, pp 1157–1174
3.
go back to reference Minardi D, Milanese G, Galosi AB, Donatelli G, Muzzonigro G (2004) Persistent priapism and histological modifications of the erectile tissue. Two case reports. Arch Ital Urol Androl 76:97–99PubMed Minardi D, Milanese G, Galosi AB, Donatelli G, Muzzonigro G (2004) Persistent priapism and histological modifications of the erectile tissue. Two case reports. Arch Ital Urol Androl 76:97–99PubMed
4.
go back to reference Zheng DC, Yao HJ, Zhang K, Xu MX, Chen Q, Chen YB, Cai ZK, Lu MJ, Wang Z (2013) Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature. Asian J Androl 15:75–78PubMedCrossRefPubMedCentral Zheng DC, Yao HJ, Zhang K, Xu MX, Chen Q, Chen YB, Cai ZK, Lu MJ, Wang Z (2013) Unsatisfactory outcomes of prolonged ischemic priapism without early surgical shunts: our clinical experience and a review of the literature. Asian J Androl 15:75–78PubMedCrossRefPubMedCentral
5.
go back to reference Tay YK, Spernat D, Rzetelski-West K, Appu S, Love C (2012) Acute management of priapism in men. BJU Int 109(Suppl 3):15–21 PubMedCrossRef Tay YK, Spernat D, Rzetelski-West K, Appu S, Love C (2012) Acute management of priapism in men. BJU Int 109(Suppl 3):15–21 PubMedCrossRef
6.
go back to reference Merkus D, Visser M, Houweling B, Zhou Z, Nelson J, Duncker DJ (2013) Phosphodiesterase 5 inhibition-induced coronary vasodilation is reduced after myocardial infarction. Am J Physiol Heart Circ Physiol 304:1370–1381CrossRef Merkus D, Visser M, Houweling B, Zhou Z, Nelson J, Duncker DJ (2013) Phosphodiesterase 5 inhibition-induced coronary vasodilation is reduced after myocardial infarction. Am J Physiol Heart Circ Physiol 304:1370–1381CrossRef
7.
go back to reference Pyriochou A, Zhou Z, Koika V, Petrou C, Cordopatis P, Sessa WC, Papapetropoulos A (2007) The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J Cell Physiol 211:197–204PubMedCrossRef Pyriochou A, Zhou Z, Koika V, Petrou C, Cordopatis P, Sessa WC, Papapetropoulos A (2007) The phosphodiesterase 5 inhibitor sildenafil stimulates angiogenesis through a protein kinase G/MAPK pathway. J Cell Physiol 211:197–204PubMedCrossRef
9.
go back to reference Seifi B, Kadkhodaee M, Delavari F, Mikaeili S, Shams S, Ostad SN (2012) Pretreatment with pentoxifylline and N-acetylcysteine in liver ischemia reperfusion-induced renal injury. Ren Fail 34:610–615PubMedCrossRef Seifi B, Kadkhodaee M, Delavari F, Mikaeili S, Shams S, Ostad SN (2012) Pretreatment with pentoxifylline and N-acetylcysteine in liver ischemia reperfusion-induced renal injury. Ren Fail 34:610–615PubMedCrossRef
10.
go back to reference Bruno Rde B, Marques TF, Batista TM, Lima JC, de Arruda KG, Lima PF, Santos Nda S, Cunha GM, Vitor HV, Viana GS (2009) Pentoxifylline treatment improves neurological and neurochemical deficits in rats subjected to transient brain ischemia. Brain Res 1260:55–64PubMedCrossRef Bruno Rde B, Marques TF, Batista TM, Lima JC, de Arruda KG, Lima PF, Santos Nda S, Cunha GM, Vitor HV, Viana GS (2009) Pentoxifylline treatment improves neurological and neurochemical deficits in rats subjected to transient brain ischemia. Brain Res 1260:55–64PubMedCrossRef
11.
go back to reference Sanli O, Armagan A, Kandirali E, Ozerman B, Ahmedov I, Solakoglu S, Nurten A, Tunç M, Uysal V, Kadioglu A (2004) TGF-beta1 neutralizing antibodies decrease the fibrotic effects of ischemic priapism. Int J Impot Res 16:492–497PubMedCrossRef Sanli O, Armagan A, Kandirali E, Ozerman B, Ahmedov I, Solakoglu S, Nurten A, Tunç M, Uysal V, Kadioglu A (2004) TGF-beta1 neutralizing antibodies decrease the fibrotic effects of ischemic priapism. Int J Impot Res 16:492–497PubMedCrossRef
12.
go back to reference Roghmann F, Becker A, Sammon JD, Ouerghi M, Sun M, Sukumar S, Djahangirian O, Zorn KC, Ghani KR, Gandaglia G, Menon M, Karakiewicz P, Noldus J, Trinh QD (2013) Incidence of priapism in emergency departments in the United States. J Urol 190:1275–1280 PubMedCrossRef Roghmann F, Becker A, Sammon JD, Ouerghi M, Sun M, Sukumar S, Djahangirian O, Zorn KC, Ghani KR, Gandaglia G, Menon M, Karakiewicz P, Noldus J, Trinh QD (2013) Incidence of priapism in emergency departments in the United States. J Urol 190:1275–1280 PubMedCrossRef
13.
go back to reference Kadioglu A, Sanli O, Celtik M, Cakan M, Taskapu H, Akman T (2006) Practical management of patients with priapism. EAU-EBU Updat Ser 4:150–160CrossRef Kadioglu A, Sanli O, Celtik M, Cakan M, Taskapu H, Akman T (2006) Practical management of patients with priapism. EAU-EBU Updat Ser 4:150–160CrossRef
14.
go back to reference Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP (2012) A review of outcomes of an intracavernosal injection therapy programme. BJU Int 110:1787–1791PubMedCrossRef Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP (2012) A review of outcomes of an intracavernosal injection therapy programme. BJU Int 110:1787–1791PubMedCrossRef
15.
go back to reference Burnett AL, Bivalacqua TJ (2007) Priapism: current principles and practice. Urol Clin N Am 34:631–642CrossRef Burnett AL, Bivalacqua TJ (2007) Priapism: current principles and practice. Urol Clin N Am 34:631–642CrossRef
16.
go back to reference Sadeghi-Nejad H, Seftel AD (2002) The etiology, diagnosis, and treatment of priapism: review of the American Foundation for Urologic Disease Consensus Panel Report. Curr Urol Rep 3:492–498PubMedCrossRef Sadeghi-Nejad H, Seftel AD (2002) The etiology, diagnosis, and treatment of priapism: review of the American Foundation for Urologic Disease Consensus Panel Report. Curr Urol Rep 3:492–498PubMedCrossRef
17.
go back to reference Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R (2010) Priapism: pathogenesis, epidemiology, and management. J Sex Med 7:476–500PubMedCrossRef Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R (2010) Priapism: pathogenesis, epidemiology, and management. J Sex Med 7:476–500PubMedCrossRef
18.
go back to reference El-Bahnasawy MS, Dawood A, Farouk A (2002) Low-flow priapism: risk factors for erectile dysfunction. BJU Int 89:285–290PubMedCrossRef El-Bahnasawy MS, Dawood A, Farouk A (2002) Low-flow priapism: risk factors for erectile dysfunction. BJU Int 89:285–290PubMedCrossRef
21.
go back to reference Hinman F (1914) Priapism: report of cases and a clinical study of the literature with reference to its pathogenesis and surgical treatment. Ann Surg 60:689–716PubMedCrossRefPubMedCentral Hinman F (1914) Priapism: report of cases and a clinical study of the literature with reference to its pathogenesis and surgical treatment. Ann Surg 60:689–716PubMedCrossRefPubMedCentral
22.
go back to reference Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522PubMedCrossRef Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N (2002) Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136:515–522PubMedCrossRef
23.
go back to reference Fries R, Shariat K, Von WH, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985PubMed Fries R, Shariat K, Von WH, Bohm M (2005) Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation 112:2980–2985PubMed
24.
go back to reference Sharma R (2007) Novel phosphodiesterase-5 inhibitors: current indications and future directions. Indian J Med Sci 61:667–679PubMedCrossRef Sharma R (2007) Novel phosphodiesterase-5 inhibitors: current indications and future directions. Indian J Med Sci 61:667–679PubMedCrossRef
25.
go back to reference Liu Y, Shakur Y, Kambayashi J (2011) Phosphodiesterases as targets for intermittent claudication. Handb Exp Pharmacol 204:211–236PubMedCrossRef Liu Y, Shakur Y, Kambayashi J (2011) Phosphodiesterases as targets for intermittent claudication. Handb Exp Pharmacol 204:211–236PubMedCrossRef
26.
go back to reference Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, Strandness DE (1982) Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104:66–72PubMedCrossRef Porter JM, Cutler BS, Lee BY, Reich T, Reichle FA, Scogin JT, Strandness DE (1982) Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104:66–72PubMedCrossRef
27.
go back to reference Strano A, Davi G, Avellone G, Novo S, Pinto A (1984) Double blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35:459–466PubMedCrossRef Strano A, Davi G, Avellone G, Novo S, Pinto A (1984) Double blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 35:459–466PubMedCrossRef
28.
go back to reference Ladurner G, Kalvach P, Moessler H (2005) Cerebrolysin study group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm 112:415–428PubMedCrossRef Ladurner G, Kalvach P, Moessler H (2005) Cerebrolysin study group. Neuroprotective treatment with cerebrolysin in patients with acute stroke: a randomised controlled trial. J Neural Transm 112:415–428PubMedCrossRef
29.
go back to reference Toda K, Kumagai N, Kaneko F, Tsunematsu S, Tsuchimoto K, Saito H, Hibi T (2009) Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production. J Gastroenterol Hepatol 24:860–865PubMedCrossRef Toda K, Kumagai N, Kaneko F, Tsunematsu S, Tsuchimoto K, Saito H, Hibi T (2009) Pentoxifylline prevents pig serum-induced rat liver fibrosis by inhibiting interleukin-6 production. J Gastroenterol Hepatol 24:860–865PubMedCrossRef
30.
go back to reference Ng YY, Chen YM, Tsai TJ, Lan XR, Yang WC, Lan HY (2009) Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. Am J Nephrol 29:43–53PubMedCrossRef Ng YY, Chen YM, Tsai TJ, Lan XR, Yang WC, Lan HY (2009) Pentoxifylline inhibits transforming growth factor-beta signaling and renal fibrosis in experimental crescentic glomerulonephritis in rats. Am J Nephrol 29:43–53PubMedCrossRef
31.
go back to reference Hung KY, Huang JW, Chiang CK, Tsai TJ (2008) Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies. Nephrol Dial Transpl 23:3831–3840CrossRef Hung KY, Huang JW, Chiang CK, Tsai TJ (2008) Preservation of peritoneal morphology and function by pentoxifylline in a rat model of peritoneal dialysis: molecular studies. Nephrol Dial Transpl 23:3831–3840CrossRef
32.
go back to reference Flechner L, Breyer BN, Eisenberg ML, Lue TF (2011) Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl 13:322–325PubMedCrossRefPubMedCentral Flechner L, Breyer BN, Eisenberg ML, Lue TF (2011) Pentoxifylline treatment and penile calcifications in men with Peyronie’s disease. Asian J Androl 13:322–325PubMedCrossRefPubMedCentral
33.
go back to reference Lin G, Shindel AW, Banie L (2010) Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 7:1787–1797PubMedCrossRefPubMedCentral Lin G, Shindel AW, Banie L (2010) Pentoxifylline attenuates transforming growth factor-beta1-stimulated elastogenesis in human tunica albuginea-derived fibroblasts part 2: interference in a TGF-beta1/Smad-dependent mechanism and downregulation of AAT1. J Sex Med 7:1787–1797PubMedCrossRefPubMedCentral
34.
go back to reference Albersen M, Fandel TM, Zhang H, Banie L, Lin G, De Ridder D, Lin CS, Lue TF (2011) Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction. Eur Urol 59:286–296PubMedCrossRefPubMedCentral Albersen M, Fandel TM, Zhang H, Banie L, Lin G, De Ridder D, Lin CS, Lue TF (2011) Pentoxifylline promotes recovery of erectile function in a rat model of postprostatectomy erectile dysfunction. Eur Urol 59:286–296PubMedCrossRefPubMedCentral
35.
go back to reference Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M (2013) A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol 69:1057–1073PubMedCrossRef Nasiri-Toosi Z, Dashti-Khavidaki S, Khalili H, Lessan-Pezeshki M (2013) A review of the potential protective effects of pentoxifylline against drug-induced nephrotoxicity. Eur J Clin Pharmacol 69:1057–1073PubMedCrossRef
36.
go back to reference Abo-Salem OM (2013) Uroprotective effect of pentoxifylline in cyclophosphamide-induced hemorrhagic cystitis in rats. J Biochem Mol Toxicol 27:343–350PubMedCrossRef Abo-Salem OM (2013) Uroprotective effect of pentoxifylline in cyclophosphamide-induced hemorrhagic cystitis in rats. J Biochem Mol Toxicol 27:343–350PubMedCrossRef
37.
go back to reference Archer SL, Roudebush WE (2013) Enhancement of sperm motility using pentoxifylline and platelet-activating factor. Methods Mol Biol 927:241–245PubMedCrossRef Archer SL, Roudebush WE (2013) Enhancement of sperm motility using pentoxifylline and platelet-activating factor. Methods Mol Biol 927:241–245PubMedCrossRef
38.
go back to reference Savaş C, Dindar H, Aras T, Yücesan S (2002) Pentoxifylline improves blood flow to both testes in testicular torsion. Int Urol Nephrol 33:81–85PubMedCrossRef Savaş C, Dindar H, Aras T, Yücesan S (2002) Pentoxifylline improves blood flow to both testes in testicular torsion. Int Urol Nephrol 33:81–85PubMedCrossRef
39.
go back to reference Tzeng YS, Tang SH, Meng E, Lin TF, Sun GH (2004) Ischemic glans penis after circumcision. Asian J Androl 6:161–163PubMed Tzeng YS, Tang SH, Meng E, Lin TF, Sun GH (2004) Ischemic glans penis after circumcision. Asian J Androl 6:161–163PubMed
40.
go back to reference Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ (2005) Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 16:2702–2713PubMedCrossRef Lin SL, Chen RH, Chen YM, Chiang WC, Lai CF, Wu KD, Tsai TJ (2005) Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 16:2702–2713PubMedCrossRef
41.
go back to reference Evliyaoğlu Y, Kayrin L, Kaya B (1997) Effect of pentoxifylline on veno-occlusive priapism-induced corporeal tissue lipid peroxidation in a rat model. Urol Res 25:143–147PubMedCrossRef Evliyaoğlu Y, Kayrin L, Kaya B (1997) Effect of pentoxifylline on veno-occlusive priapism-induced corporeal tissue lipid peroxidation in a rat model. Urol Res 25:143–147PubMedCrossRef
42.
go back to reference Rajfer J, Gore JL, Kaufman J, Gonzalez-Cadavid N (2006) Case report: avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide. J Sex Med 3:173–176PubMedCrossRef Rajfer J, Gore JL, Kaufman J, Gonzalez-Cadavid N (2006) Case report: avoidance of palpable corporal fibrosis due to priapism with upregulators of nitric oxide. J Sex Med 3:173–176PubMedCrossRef
Metadata
Title
The effect of pentoxifylline on penile cavernosal tissues in ischemic priapism-induced rat model
Authors
Fikret Erdemir
Fatih Firat
Fatma Markoc
Dogan Atilgan
Bekir Suha Parlaktas
Yunus Emre Kuyucu
Yusuf Gencten
Publication date
01-10-2014
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 10/2014
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-014-0769-z

Other articles of this Issue 10/2014

International Urology and Nephrology 10/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.